TNFSF11 and osteoporosis: As RANKL has been identified as one of the critical cytokines that regulates osteoclast formation and activity,18, 19 inhibiting RANKL‐induced osteoclastogenesis was considered to be a potential therapeutic strategy for osteoporosis.